Dr. Gainer is Chair of the Board of HRA Pharma. Before that she was CEO of the company for 7 years. Over her tenure, company’s revenues more than tripled and profits increased 10-fold. Dr. Gainer joined HRA Pharma in 2000 in order to lead the development of the new chemical entity, ulipristal acetate. As Executive Director of Research and Development, she spent nearly a decade managing HRA Pharma's global R&D program focused on designing innovative products that respond to unmet medical needs in the fields of reproductive health and rare endocrine disease. She is the author/inventor of dozens of peer-reviewed publications and patents.

 Ms. Bergmann is a highly experienced consumer products executive with more than 30 years of success in leadership roles with leading consumer companies, including Sara Lee, Schering-Plough and Johnson & Johnson.  She managed the global women’s health business at Johnson & Johnson and remains involved in women’s issues through her service to two non-profit boards, EngenderHealth and Women in Need. She is currently an Adjunct Professor in Marketing and General Management at New York University (NYU). 

Mr. Bruun is a managing director in the Merchant Banking Division (MBD) of Goldman Sachs in London. He is responsible for corporate European healthcare and nutrition investing and corporate investing in Scandinavia. Previously, he was an associate in the Nordic Mergers & Acquisitions team in the Investment Banking Division (IBD). He joined Goldman Sachs in 2004, became managing director in 2013 and was named partner in 2016.

Ms. Charpentier is a Director in the Investment team of Astorg Partners. Prior to joining Astorg Partners, Ms. Charpentier was an Associate at Fondations Capital Services France SASU, a private equity fund in Paris. She started her career in 2005, as a Principal in the M&A Division of Morgan Stanley in Paris, before joining the Media and Telecommunication division in New York.

 Mr. Colpman brings over 30 years of broad experience in business development to HRA Pharma. He is the founder of Colpman Consulting Ltd, a company providing strategic advice to a variety of biotech and pharma companies. Previously he headed business development and licensing at Shire PLC  and has also held various BD roles at Purdue, Novo Nordisk A/S, Boots Pharmaceuticals and Glaxo. Mr. Colpman is on the Board of Orexo AB a specialty pharmaceutical company commercialising a product for opioid dependence.  

Dr. Corn brings in-depth scientific, medical and regulatory knowledge to HRA Pharma. He was previously Chief Medical Officer at Jazz Pharmaceuticals International plc (formerly EUSA Pharma) and Zeneus Pharma. He has held senior clinical and regulatory positions at GlaxoWellcome, MSD Research Laboratories, Athena Neuroscience and Elan as well as in the UK regulatory agency. Dr. Corn has played a key role in more than twenty regulatory approvals in USA and Europe and has solid experience both as a board member and chair of a number of healthcare companies and charities.

 Mr. Lieven is an Analyst and member of the Investment team of Astorg Partners. Prior to this, he worked for three years in the infrastructure investment division of 3i. Mr. Lieven started his career at Barclays Infrastructure Funds in 2012.

Ms. Omar Broca is Executive Director with Goldman Sachs in London since 2007. Her area of expertise is private equity. Previously, Scarlett Omar-Broca worked as an Analyst with Merrill Lynch.

 Mr. Timsit is the Co-Founder and a Managing Partner and Owner of Astorg Partners. He is a member of the Investment team. Additionally, he is in charge of the company’s Investor Relations team. Prior to this, he spent 4 years with the private equity team at Suez. He began his carrier in 1989 at Banque Indosuez where he held several positions in London and Paris, particularly in the project finance division. 

Dr. Ulmann is the Founder of HRA Pharma, a company he led from 1996 to 2009 as CEO, then he chaired until 2016. Currently he is the CEO of CEMAG Consulting and serves as a consultant for several start-up companies. Before founding HRA Pharma, Dr. Ulmann served as Medical Director and Head of Clinical Research for Roussel-Uclaf and Hoechst-Marion-Roussel. Prior to that, he was international project leader for the development of RU-486, then medical director of Laboratoire Roussel, France. He began his career as a physician at the Necker Hospital of Paris.